France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

Viking Therapeutics ' ( VKTX 0.28%) shares could rise over the next year by as much as 165% at the midpoint according to some ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.

Meanwhile, Dupixent is on its way to biopharma superstardom. Sanofi executives recently raised their sales projection to 13 billion euros thanks to strong expected uptake across a range of diseases.

Aside from Dupixent, Regeneron's eye injection Eylea continues to deliver in its eighth year on the market, as U.S. sales grew 9% year over year to $1.07 billion.

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...